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IntroductIon
Sex cord-stromal tumors comprise a group of ovar-
ian neoplasms with different as well as overlapping 
histological, immunohistochemical and clinical char-
acteristics. Various antibodies have been recently used 
in order to define the immunoprofile of each category, 
including CD99 and Melan-A.
CD99 (Cluster of Differentiation 99) also known 
as MIC2 or single-chain type-1 glycoprotein is a hu-
man protein encoded by the CD99 gene. It is a cell 
surface glycoprotein involved in leukocyte migration, 
T-cell adhesion, ganglioside GM1 and transmembrane 
protein transport, and T-cell death by a caspase-inde-
pendent pathway1. In addition, the encoded protein 
may have the ability to rearrange the actin cytoskel-
eton and may also act as an oncosuppressor in osteo-
sarcoma. Cyclophilin A binds to CD99 and may act as 
a signaling regulator of CD992. This gene is found in 
the pseudoautosomal region of chromosomes X and 
Y and escapes X-chromosome inactivation. Two tran-
script variants encoding different isoforms have been 
found for this gene.
The MART-1 / Melan-A antigen is specific for the 
melanocyte lineage, found in normal skin, the retina, 
and melanocytes. It is thus useful as a marker for 
melanocytic tumors (melanomas) with the caveat that 
it is normally found in benign nevi as well3. MART-1 / 
Melan-A is a putative 18 kDa transmembrane protein 
consisting of 118 amino acids. It has a single trans-
membrane domain. The Melan-A/MART-1 antigen 
is also expressed in Leydig cells, adrenal tissue, and 
steroid-secreting tumors4.
The reason we have undertaken this investigation 
is because fibromas/fibrothecomas is the least studied 
category within this group.
MAtErIAL And MEtHodS
Our study includes 26 consecutive cases diagnosed as 
ovarian fibromas or fibrothecomas during the last six 
years. For each case hematoxylin and eosin-stained 
slides were evaluated to confirm the original diagno-
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sis. Tumors were classified as fibromas or fibrotheco-
mas (unclassified tumors of thecoma-fibroma group 
according to WHO, 20035) using standard criteria 
(WHO, 20035). Immunohistochemical detection of 
CD99 and Melan-A was performed on formalin-fixed, 
paraffin-embedded tissue sections, 3-μm in thickness. 
High temperature antigen unmasking in electric pres-
sure cooker, and TrilogyTM solution (Cell Marque, 
Rocklin, CA, USA) pretreatment preceded the main 
procedure. A standardised automated (Nexes, Ven-
tana, Tuscon, AZ, USA), streptavidin-biotin method 
(I-VIEW Paraffin DAB, Ventana) followed the appli-
cation of the monoclonal antibodies. The latter were 
directed against CD99 (clone HO36-1.1, Novocastra, 
Newcastle, UK) with a dilution of 1:50, and Melan-A 
(clone A103, Dako, Glostrup, Denmark) with a dilu-
tion of 1:50. An adult granulosa tumor with diffuse 
3+ positivity for CD99, and a malignant melanoma 
with diffuse 3+ positivity for Melan-A were used as 
positive controls. A negative control for immunostain-
ing was carried out by replacing the primary antibody 
with non-immune rabbit serum. The intensity of stain-
ing was graded as either absent, weak, moderate or 
strong (0 to 3 scale). 
rESuLtS
Fourteen tumors were regarded as ovarian fibromas, 
while the rest 12 as fibrothecomas. One fibroma was 
bilateral. Nine tumors (34.6%) were positive to CD99, 
while all tumors were negative to Melan-A. More spe-
cifically 8/14 (57,14%) fibromas, and 1/12 (8,33%) fi-
brothecomas were CD99-positive. Six out of the eight 
CD99-positive fibromas presented 2+ score (figures 1 
and 2), and the remaining two had 1+ staining score. 
The single positive fibrothecoma presented 1+ stain-
ing reaction.
dIScuSSIon
Fibromas are stromal tumors of the ovary composed 
of spindle, oval or round cells producing collagen5. 
They account for 4% of all ovarian tumors, and they 
are most common in the middle age. Fibromas may be 
found incidentally, but when large may present with 
no-specific signs and symptoms of a pelvic mass. Ten 
to fifteen percent of fibromas larger than 10 cm may 
be accompanied by ascites and/or pleural effusion 
(Meigs syndrome). Ovarian fibromas are considered 
benign neoplasms. However, rare cellular fibromas 
may recur in the pelvis or upper abdomen, sometimes 
after a long interval. Fibromas have some common 
features with thecomas, and in essence these two cat-
egories form a continuous spectrum of stromal ovar-
ian tumors that includes those composed entirely of 
fibroblasts producing collagen (fibromas), those con-
taining predominantly theca cells (thecomas), and in 
between fibrothecomas that contain both components 
in various proportions. 
Many immunohistochemical markers have been 
Figure 1. Fibroma with moderate positivity to CD99 anti-
body. (DAB, hematoxylin, 100X).
Figure 2. Many fibroma cells present immunoreactivity to 
CD99 (DAB, hematoxylin, 400X).
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previously studied in various types of ovarian sex 
cord-stromal tumors6-10. The limited literature for these 
tumors shows that sensitivity for sex cord-stromal lin-
eage may vary between markers, while some markers 
may not be as sensitive in some types of sex cord-
stromal tumors compared with other tumors in this 
spectrum of neoplasms. In the largest published se-
ries, Zhao et al reported that SF-1 is the most sensitive 
sex cord-stromal marker among the most common 
types of sex cord-stromal tumors6. The most informa-
tive sex cord-stromal markers for the distinction from 
nonsex cord-stromal tumors are considered to be in-
hibin, calretinin, SF-1, and WT1. Melan-A expression 
seems to be restricted to the Leydig cell component 
of these tumors. In addition, Zhao et al noted that 
utility of immunohistochemistry for the diagnosis of 
fibroma/fibrothecoma is somewhat limited, and also 
that CD99 is negative in these tumors. In contrast to 
the findings of this large series, we found that some 
of fibromas/fibrothecomas are CD99-positive. Most 
impressively this positivity concerns more than half 
of the pure fibromas. We conclude that CD99, which 
is widely present in various other tumors, may be fre-
quently expressed in ovarian fibromas, especially the 
ones with pure fibromatous histology. This finding has 
to be confirmed from other studies, since this category 
of tumors is the least tested within the sex cord-strom-
al tumors group.
ΠΕΡΙΛΗΨΗ: Οι όγκοι γεννητικής ταινίας-στρώματος αποτελούν μία ομάδα νεοπλασμάτων της ωοθήκης με διαφορετικά, 
αλλά και αλληλεπικαλυπτόμενα ιστολογικά, ανοσοϊστοχημικά και κλινικά χαρακτηριστικά.  Διάφορα αντισώματα έχουν 
χρησιμοποιηθεί πρόσφατα προκειμένου να καθορισθεί ο ανοσοφαινότυπος της κάθε κατηγορίας, συμπεριλαμβανομένων 
των CD99 και Melan-A. Ο λόγος που διενεργήσαμε αυτή τη μελέτη ήταν ότι τα ινώματα και τα ινοθηκώματα είναι η 
λιγότερο μελετημένη κατηγορία μέσα σε αυτή την ομάδα. Στην εργασία μας περιλαμβάνονται 26 ινώματα και ινοθηκώματα, 
τα οποία υποβλήθηκαν σε ανοσοϊστοχημική διερεύνηση με CD99 και Melan-A. H ανοσοϊστοχημική αντίδραση αξιολογή-
θηκε σε κλίμακα απο 0 έως 3. Εννέα όγκοι (34,6%) ήταν θετικοί στο CD99, έξη με αντίδραση +2 και τρεις με αντίδραση 
+1. Όλοι οι όγκοι ήταν αρνητικοί στο Melan-A. Συμπεραίνουμε ότι σε αντίθεση με ότι είναι γνωστό από την περιορισμένη 
βιβλιογραφία για τον ανοσοφαινότυπο των ινωμάτων και ινοθηκωμάτων της ωοθήκης, μερικά από αυτά εμφανίζουν μία 
ήπια έως μέτρια θετική αντίδραση στο CD99.
Λέξεις Κλειδιά: Ωοθήκη, Ίνωμα, Ινοθήκωμα, CD99, Melan-A.
Ανοσοϊστοχημική αντίδραση του CD99 και Melan-A στα ινώματα  
και τα ινοθηκώματα της ωοθήκης.
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